News Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Aug 01, 2019-ET-105 assigned Prescription Drug User Fee Act (PDUFA) target action date of March 17, 2020
DEER PARK, Ill., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Aug 01, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 1, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Aug 01, 2019Final study results accepted for “Late Breaking Presentation” on October 16, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that the NATESTO® Spermatogenesis Study results have been accepted for presentation as a...
- Jul 30, 2019
DEER PARK, Ill., July 30, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Jul 30, 2019Acerus Pharmaceuticals to launch U.S. specialty sales force of at least 25 representatives
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that it will be taking an expanded role in the commercialization of NATESTO® in the U.S. The...
- Jul 29, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its second quarter 2019 financial and operating results on Wednesday, August 7, 2019 before the...
- Jul 24, 2019NATESTO® Now Covered on Payer Plans Covering Over 6 Million U.S. Lives
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) (“Acerus” or the “Company”) announced today that NATESTO® (testosterone nasal gel) is now on formulary...
- Jul 19, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB:ASPCF) today announced that it has entered into a US$5 million subordinated...
- Jul 18, 2019
MIAMI, July 18, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- Jul 18, 2019
FARMINGDALE, N.Y., July 18, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Jul 12, 2019
DEER PARK, Ill., July 12, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Jul 11, 2019Exclusion of long-term desensitization and patient quality-of-life data by ICER fails to recognize the full value AR101 immunotherapy can deliver to the peanut allergy community
BRISBANE, Calif.--(BUSINESS WIRE)--Jul. 11, 2019-- Aimmune Therapeutics (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, cautions stakeholders...
- Jul 11, 2019Enteris BioPharma’s “Feasibility-to-Licensing” Partner, Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™ for Pruritus in Patients with Atopic Dermatitis
Boonton, NJ – July 11, 2019 – Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary oral peptide delivery technologies,...
- Jul 10, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX: ASP, OTCQB: ASPCF) (“Acerus” or the “Company”) announced today an update relative to the Company’s NATESTO® business....
- Jul 08, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX: ASP, OTCQB: ASPCF) (“Acerus” or the “Company”) announced today the acceptance of a new manuscript to the Journal of the...
- Jul 01, 2019
FARMINGDALE, N.Y., July 01, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Jun 28, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Jun. 28, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Jun 28, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB: ASPCF) (“Acerus” or the “Company”) today announced that it entered into an amended agreement related to its...
- Jun 27, 2019Enteris BioPharma’s “Feasibility-to-Licensing” Partner, Cara Therapeutics, Initiates Second Pruritus Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™
Boonton, NJ – June 27, 2019 – Enteris BioPharma, Inc. a biotechnology company developing innovative drug products built around its proprietary oral peptide delivery technologies, congratulates...
- Jun 27, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) (“Acerus” or the “Company”) today announced that Health Canada has completed the initial screening...
- Jun 27, 2019
Acerus Pharmaceuticals Corporation ("Acerus") (TSX:ASP) today announced the voting results from its annual meeting of shareholders held on June 27, 2019 in Toronto, Ontario. The total number of...
- Jun 26, 2019–Reached Agreement with FDA on Regulatory Package for NDA Submission Utilizing the 505(b)(2) Expedited Regulatory Pathway— — TADFIN is a First Novel Combination Formulation of Tadalafil and Finasteride for the Treatment of BPH with NDA Submission Anticipated in Summer of 2020–
MIAMI, June 26, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- Jun 20, 2019
FARMINGDALE, N.Y., June 20, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical...
- Jun 13, 2019Unique patent-pending formulation of lamotrigine addresses significant unmet need in pediatric epilepsy patients
DEER PARK, Ill., June 13, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Jun 13, 2019Moving the industry Beyond Surface Technology and into Mechanobiology
4WEB Medical, an orthopedic device company focused on developing innovative implants utilizing its proprietary Truss Implant TechnologyTM, announced today that it has closed a substantial round of...
- Jun 12, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Jun. 12, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Jun 11, 2019Company to Share Updated Clinical Data on AR101 and Provide Perspective on Its Value to Society
BRISBANE, Calif.--(BUSINESS WIRE)--Jun. 11, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, will present at...
- Jun 06, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB: ASPCF) (“Acerus” or the “Company”) today announced that it has reached a mutual agreement with Innovus...
- Jun 05, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Jun. 5, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Jun 04, 2019— VERU-100 Is a Proprietary Peptide Formulation Designed with Multiple Beneficial Clinical Attributes Addressing the Shortfalls of the Current Multi-Billion-Dollar Androgen Deprivation Therapy Market — — Reached Agreement with FDA on an Expedited Regulatory Pathway and Clinical Development Strategy —
MIAMI, June 04, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- Jun 04, 2019--APPEAL 2: Struggle to Avoid Accidental Peanut Exposure Negatively Impacts Quality of Life for Patients and Families--
LISBON, Portugal--(BUSINESS WIRE)--Jun. 4, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Jun 03, 2019
FARMINGDALE, N.Y., June 03, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Jun 02, 2019
LISBON, Portugal--(BUSINESS WIRE)--Jun. 2, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today presented...
- May 30, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (“Acerus” or “the Company”) (TSX:ASP; OTCQB:ASPCF) announced today that it has signed a patent license agreement (the...
- May 29, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that President and CEO Todd Norbe and Executive Vice President and CFO John Beaver are scheduled to present at the 9th
- May 28, 2019
MIAMI, May 28, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- May 28, 2019Enteris BioPharma to Present at New Rhein Healthcare Inaugural Industry Day 2019
Boonton, NJ – May 28, 2019 – Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary oral peptide delivery technologies, announced...
- May 24, 2019– Full Results from Phase 3 ARTEMIS Study Will Be Featured –
BRISBANE, Calif.--(BUSINESS WIRE)--May 24, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- May 21, 2019-- 4 in 10 Teens believe they have a great or very great chance or certainty of dying from accidental exposure --
NEW ORLEANS--(BUSINESS WIRE)--May 21, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- May 20, 2019
FARMINGDALE, N.Y., May 20, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- May 20, 2019
Please see supporting documents for the information about a proposed settlement of a derivative action involving the company.
- May 16, 2019- Company Enters into Commercial Supply Agreement for AR101 -
BRISBANE, Calif.--(BUSINESS WIRE)--May 16, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- May 16, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--May 16, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- May 16, 2019Hear from leading experts, including keynote speaker Gordon J. Christensen DDS, MSD, PhD, on the latest trends and innovations in dentistry
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, is proud to announce that it will host the Advancing Dentistry Symposium in San Diego, California on October 18-19, 2019. The...
- May 15, 2019— Prostate Cancer Clinical Trials Advancing; Early Clinical Observations Look Promising – — Strong Financial Results for Q2 and YTD FY 2019 — — Company to Host Investor Conference Call on Wednesday, May 15, 2019, 8 a.m. ET –
MIAMI, May 15, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU) an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- May 15, 2019
DEER PARK, Ill., May 15, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- May 15, 2019Total revenues of approximately $9.4 million for the first quarter of 2019 compared to $6.8 million for the first quarter of 2018.
Dallas, TX, May 15, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its first quarter 2019 financial results.
- May 13, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three-month period ended March...
- May 13, 2019
Lake Forest, CA – May 13, 2019 – Tenex Health, Inc., a privately held U.S.-based medical technology company providing healthcare professionals with minimally invasive technologies to treat...
- May 09, 2019First Quarter U.S. Laser Revenue Increased 18% Year-Over-Year
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today reported net revenue of $10.3 million for the first quarter ended March 31, 2019, an increase of 3% compared to the first...